Trials / Terminated
TerminatedNCT00398840
A Study of ARQ 171 in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation Study of ARQ 171 in Adult Patients With Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, dose escalation study of ARQ 171 administered via intravenous infusion (IVI) into a peripheral vein weekly. Patients with advanced solid tumors, who are refractory to available therapy or for whom no standard systemic therapy exists, will be enrolled.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARQ 171 |
Timeline
- Start date
- 2006-11-01
- Primary completion
- 2008-09-01
- Completion
- 2008-09-01
- First posted
- 2006-11-14
- Last updated
- 2017-03-06
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00398840. Inclusion in this directory is not an endorsement.